AUTHORS
Yi Xiang, PhD, Min Wu, PhD2, Srikanth Venkatraman, PhD3, Yue Chen, MS4
AFFILIATIONS
1 Disc Medicine Inc., Watertown, Massachusetts, United States
2 Disc Medicine Inc., Watertown, Massachusetts, United States
3 Disc Medicine Inc., Watertown, Massachusetts, United States
4 Disc Medicine Inc., Watertown, Massachusetts, United States
ABSTRACT
Background: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are inherited disorders of heme biosynthesis caused by pathogenic variants in ferrochelatase (FECH) and 5′-aminolevulinic acid synthase-2 (ALAS2), respectively, resulting in accumulation of metal-free protoporphyrin IX (PPIX) in erythroid cells, skin, and liver. In addition to photosensitivity and potential liver disease, accumulating evidence suggests that excess PPIX contributes to systemic inflammation and erythrocyte dysfunction (Di Pierro et al, Diagnostics 2022; Granata et al, Immunol Res 2019; Granata et al, Front Immunol 2021; Sil et al, J Biosci 2004). Glycine transporter 1 (GlyT1) mediates glycine uptake into erythroid precursors for heme synthesis. GlyT1 inhibition reduces substrate availability for porphyrin synthesis and lowers PPIX production. The GlyT1 inhibitor bitopertin reduced whole-blood PPIX in Phase 2 studies (Yeung et al, J Am Acad Dermatol 2026; Ross et al, Clin Exp Dermatol 2026) and is currently being evaluated in a Phase 3 study (NCT06910358) for EPP.
Aims: To characterize inflammatory and erythrocyte abnormalities associated with excess PPIX accumulation and determine whether these phenotypes are reversible by GlyT1 inhibition.
Methods: Homozygous Fechm1Pas/Fechm1Pas mice (~5% residual FECH activity) (Abitbol et al, Am J Physiol Gastrointest Liver Physiol 2005) were compared with age-matched wild-type (WT) controls. Hematology, serum cytokines, and red blood cell (RBC) morphology were evaluated. Ten-week-old EPP mice received vehicle or the selective GlyT1 inhibitor DISC-E (15 mg/kg, oral, twice daily) for 28 days. PPIX, hematologic parameters, and cytokines were assessed, and RBC morphology was evaluated by a pathologist on Day 28 (or Day 24). Key findings were confirmed in an independent study using a second GlyT1 inhibitor (DISC-C).
Results: Compared with WT mice, EPP mice exhibited chronic leukocytosis characterized by 1 to 2-fold increases in white blood cells (WBCs), neutrophils, lymphocytes, and monocytes. Serum IL-6 and TNF-α increased approximately 7.3- and 2-fold, respectively, consistent with chronic systemic inflammation. Blood smears demonstrated predominantly microcytic, hypochromic erythrocytes with significantly increased RBC fragmentation, suggesting impaired membrane integrity associated with PPIX accumulation.
DISC-E reduced RBC PPIX by 47% on Day 28 (p<0.0001), compared with vehicle. GlyT1 inhibition decreased total WBCs by 24% (p<0.05) and neutrophils by 44% (p<0.01), accompanied by reductions in serum IL-6 (-57%, p<0.05) and TNF-α (-35%, p<0.05). RBC morphology also improved, with a ~50% reduction in fragmented RBCs (p<0.0001) and markedly decreased hypochromia. Similar findings were observed with DISC-C, and inflammatory cell counts positively correlated with RBC PPIX levels.
Conclusions: These studies identify chronic inflammation and impaired erythrocyte membrane integrity as previously underrecognized consequences of excess PPIX accumulation in EPP. Pharmacologic GlyT1 inhibition not only reduced PPIX production but also reversed inflammatory and RBC abnormalities, providing mechanistic evidence that lowering PPIX may deliver therapeutic benefits beyond improving photosensitivity. These findings further support GlyT1 inhibition as a disease-modifying therapeutic strategy for EPP and XLP.
DISCLOSURES
Yi Xiang, PhD: Disc Medicine Inc - Current equity holder in publicly-traded company; Disc Medicine Inc - Stock (publicly traded); Disc Medicine Inc - Divested equity in a private or publicly-traded company in the past 24 months; Disc Medicine Inc - Current Employment